PRLR and neoplasm: Additionally, PRLR and SOCS2 could promote the expression of phosphoinositide-3 kinase (PI3K) and programmed death ligand 1 (PD-L1), which can protect tumor cells from T cell-mediated immune surveillance, and immune checkpoint blockade (ICB) therapies.